FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Responses	5)														
Name and Address of Reporting Person * Lin Patrick				2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Other (specify below) Chief Business - Strategy Off						
(Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106				08/0	3. Date of Earliest Transaction (Month/Day/Year) 08/05/2022											
(Street) HANOVER, MD 21076				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City		(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned						wned						
1.Title of Security (Instr. 3)		Date	2. Transaction Date (Month/Day/Yea	Exec (r) any		(Instr. 8)		4. Securities Acquired (A) or Disposed of (D (Instr. 3, 4 and 5)		Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		following (s)	Ownership Form:	Beneficial		
					(Month/Day/Ye		Code	V	V Amount (A) or (D) Price			(Direct (D) or Indirect I) Instr. 4)	Ownership (Instr. 4)		
Common	Stock		08/05/2022				M		7,601	A	<u>(1)</u>	440,991		I)	
Common Stock 08/05/202		08/05/2022				F		2,656	D	\$ 3.17	438,335		Г)		
								Dor								
			Table II					cor the red, I	tained i form dis Disposed	n this fo splays a of, or Be	rm ar curre	e not requently valid	uired to res I OMB cont	ormation spond unles rol number.	s	474 (9-02)
1 Title of	12	2. Tromanation		(e.g.,]	outs, calls,	, wa	rrants, o	the red, I	tained i form dis Disposed s, conver	n this fo splays a of, or Ber tible secu	rm ar curre neficia	e not requently validable ally Owned	uired to res	spond unles rol number.	s	
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/	n 3A. Deeme Execution I	(e.g.,] d Date, if	4. Transactic	, wan	rrants, o	red, I option 6. I and (M	tained i form dis Disposed	n this fo splays a of, or Ber tible secu cisable on Date	rm ar curre neficia irities 7. 7 Am Und Sec	e not requently valid	8. Price of	spond unles	f 10. Ownersh Form of Derivativ Security: Direct (L or Indirec	11. Naturip of Indire Beneficise Ownersh (Instr. 4)

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Lin Patrick C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076			Chief Business - Strategy Off				

Signatures

/s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact	08/09/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vesting of time-based shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.